Summary
1Q delivered higher revenue but lower profits. However, management described revenue and all profit lines as "tracking firmly in line with the initial plan," which frames the decline as within budget. The key question for 2Q results is whether profits recover in the standalone 2Q period, which generated JPY 1,200M of operating income in the prior-year quarter (our estimate). The operating income decline reflected one-off costs from the Tokyo head office relocation, planned growth investment in the brand businesses, and margin pressure from two specific projects. By segment, the Package business posted the largest profit decline. How far revenue growth, led by the GAKUEN series, can absorb this investment burden will be a key gauge of payback on the medium-term management plan. We will also check whether margin pressure from specific DX&SI projects has run its course, and whether the net income and EPS targets are maintained following the impairment on the employee dormitory.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Company-Wide Profit ProgressYoY change in 1H cumulative Operating Income and Recurring Profit, and progress against full-year plan | 1Q Recurring Profit reached 9.6% of the full-year plan (our estimate). Achieving the JPY 4,200M full-year target requires Recurring Profit from 2Q onward to grow +8.2% YoY (our estimate). |
Payback on Growth InvestmentSegment profit trends in the Package and Medical Big Data businesses | 1Q segment profit was JPY 280M (-24.8%) for Package and JPY 31M (-40.1%) for Medical Big Data. Whether revenue growth begins to absorb the investment burden is the key yardstick for assessing the medium-term plan. |
DX&SI ProfitabilityMargin impact of specific projects and Gross Profit Margin | 1Q Gross Profit Margin was 24.7% (27.4% in the prior-year period, our estimate). DX&SI secured 5.7% revenue growth on higher prime-contract revenue; normalized margins would support profit growth. |
Extraordinary Losses / Capital PolicyProgress on dormitory sale, Net Income Attributable to Owners of Parent Company, reflection of share buybacks | Despite an impairment loss of JPY 155M, the Net Income plan of JPY 2,950M (+12.5%) was left unchanged. As share buybacks feed into the share count, we will check whether the net income forecast and buyback-adjusted EPS forecast are updated, along with the underlying assumptions. |
Corporate Expenses / OverseasG&A related to Tokyo head office relocation and Global business P&L | 1Q corporate expenses were JPY 693M (+4.3%). We will check the level of one-off relocation costs in 2Q and whether they taper off in 2H. The Global business posted an operating loss of JPY 48M (JPY 89M loss in the prior-year period); we will check whether the improvement continues. |
Key Issues from Previous Results (FY3/2027 1Q Results)
FY3/2027 1Q revenue was JPY 7,437M (+5.6%) and operating income JPY 390M (-21.0%). All four segments grew revenue, but profits declined due to growth investment under the medium-term plan and margin pressure from specific DX&SI projects. Management described progress as on plan and maintained full-year guidance. 2Q results will show whether the company is moving from an investment-led phase toward profit recovery.
1. 1H Profit Recovery and Progress Toward Full-Year Plan
- Previous Quarter: 1Q Recurring Profit was JPY 402M (-21.0%), or 9.6% of the JPY 4,200M full-year plan (our estimate).
- Previous Quarter: Over the past four fiscal years, 1Q Recurring Profit averaged 9.7% of full-year actuals (our estimate).
- To Verify This Quarter: Standalone 2Q operating income in the prior year was JPY 1,200M (our estimate), making this a period of substantial profit accumulation.
- To Verify This Quarter: We will check how close 1H cumulative operating income comes to the prior-year JPY 1,693M. Whether management maintains its "on plan" assessment is also a focal point.
- Key Metrics: YoY change in 1H cumulative Operating Income and Recurring Profit; YoY change in standalone 2Q Operating Income (vs. JPY 1,200M).
- Key Metrics: Any revision to full-year guidance.
2. Balancing Growth Investment and Revenue Growth in Package and Medical Big Data
- Previous Quarter: Package revenue was JPY 1,444M (+3.3%), driven by strong resale of procured products in the GAKUEN series.
- Previous Quarter: However, segment profit fell to JPY 280M (-24.8%) on growth investment and the build-out of a consulting organization.
- Previous Quarter: The decline in Package segment profit accounted for most of the JPY 103M decrease in company-wide operating income (our estimate).
- Previous Quarter: Medical Big Data revenue was JPY 650M (+15.0%), driven by strong analytics and medical claims review services.
- Previous Quarter: Segment profit was JPY 31M (-40.1%) due to organizational strengthening.
- To Verify This Quarter: We want to see whether the investment burden persists at 1Q levels or is increasingly absorbed by revenue growth.
- To Verify This Quarter: We will also check the margin impact of GAKUEN product resale.
- Key Metrics: YoY change in 1H cumulative revenue and segment profit for both segments; change in segment margins from 1Q.
3. Resolution of Project-Specific Margin Pressure in DX&SI
- Previous Quarter: Revenue was JPY 4,850M (+5.7%), supported by solid prime-contract projects, mainly in manufacturing and financial services/securities/insurance.
- Previous Quarter: Margin pressure from specific projects held segment profit flat YoY at JPY 820M (-0.2%).
- Previous Quarter: Company-wide Gross Profit Margin fell to 24.7% (27.4% in the prior-year period, our estimate).
- Previous Quarter: The provision for contract losses rose to JPY 122M from JPY 114M at the prior fiscal year-end.
- To Verify This Quarter: We will check when the impact of these projects ends. We also want management commentary on any additional losses or provisions in 2Q.
- To Verify This Quarter: A margin recovery in the core business would raise confidence in a company-wide profit recovery.
- Key Metrics: YoY change in 1H cumulative DX&SI segment profit; company-wide Gross Profit Margin (28.8% in prior-year 1H); provision for contract losses balance.
4. Impact of Extraordinary Losses and Net Income/EPS Plan
- Previous Quarter: The company decided to sell its employee dormitory in Hirakata, Osaka Prefecture, and booked a JPY 155M impairment loss as an extraordinary loss.
- Previous Quarter: As a result, quarterly Net Income Attributable to Owners of Parent Company was JPY 113M (-64.8%), underperforming the Recurring Profit growth rate (-21.0%).
- Previous Quarter: Quarterly net income attributable to non-controlling interests rose to JPY 28M from JPY 6M in the prior-year period.
- To Verify This Quarter: The full-year Net Income plan of JPY 2,950M (+12.5%) remains unchanged despite the impairment.
- To Verify This Quarter: The recoverable amount was measured at the expected sale price. We want to confirm whether the sale has closed and the timing of any gain or loss on sale.
- To Verify This Quarter: "Other" current assets rose to JPY 1,361M (JPY 374M at prior fiscal year-end). Management cited higher suspense payments related to share buybacks as the main driver (JPY 1,361M vs. JPY 374M at prior fiscal year-end).
- To Verify This Quarter: We will check how the buybacks are reflected in treasury shares at 2Q-end and in the average share count for the period.
- Key Metrics: Breakdown of extraordinary gains/losses; interim Net Income Attributable to Owners of Parent Company; interim net income attributable to non-controlling interests.
- Key Metrics: Treasury shares at 2Q-end; interim EPS (JPY 44.77 in the prior-year period).
5. Tokyo Head Office Relocation Costs and Global Business P&L Improvement
- Previous Quarter: G&A not allocated to reportable segments was JPY 693M (+4.3%), which management attributed to one-off costs from the Tokyo head office relocation.
- Previous Quarter: Global business revenue was JPY 491M (+0.8%) with an operating loss of JPY 48M (vs. a JPY 89M loss in the prior-year period), narrowing the deficit.
- Previous Quarter: The narrower loss reflected higher contract development revenue at the Thailand base and lower depreciation following the impairment of fixed assets at the Malaysian subsidiary at the prior fiscal year-end.
- To Verify This Quarter: We will check the level of one-off relocation costs in 2Q and whether they taper off in 2H. Lower depreciation stems from the Malaysian impairment and should persist from 2Q onward; we also want to see whether revenue growth at the Thailand base continues.
- Key Metrics: YoY change in segment profit adjustments (corporate expenses); YoY change in 1H cumulative Global business operating income/loss.
Key Timely Disclosures This Period
- 2026/10/28Notice Regarding Dividend of Surplus (Interim Dividend) - Resolved an interim dividend of JPY 15 per share, in line with forecast. The annual dividend forecast of JPY 50 was maintained.
- 2026/10/01Notice Regarding Status of Share Buyback (similar disclosure also issued on 9/01) - Progress on buybacks linked to the buyback-related suspense payments booked at 1Q-end. These will be reflected in treasury shares at 2Q-end and the average share count for the period, providing a basis to verify the assumptions behind the EPS plan of JPY 119.34.
Previous Quarter Results (FY3/2027 1Q Actual)
The company operates four segments. Its core DX&SI business handles contract development. The Package business offers the "GAKUEN" university management system series, the Medical Big Data business provides analytics and medical claims review services, and the Global business operates bases in Thailand and Malaysia. For FY3/2027, the company plans revenue of JPY 34,300M (+5.7%) and operating income of JPY 4,150M (+6.1%). Under its medium-term plan, it is investing in talent development and training and strengthening its offering business. In 1Q, all segments grew revenue, but profits declined on growth investment and project-specific margin pressure. Management described progress as on plan.
| Item | Amount | YoY | vs. Company Plan | Remarks |
|---|---|---|---|---|
| Revenue | JPY 7,437M | +5.6% | - | Prime-contract projects in DX&SI and Medical Big Data drove growth. Progress vs. full-year plan: 21.7% (our estimate) |
| Operating Income | JPY 390M | -21.0% | - | Gross Profit Margin of 24.7% (27.4% in the prior-year period, our estimate). Package business growth investment was the main driver |
| Recurring Profit | JPY 402M | -21.0% | - | Progress vs. full-year plan: 9.6% (our estimate) |
| Net Income | JPY 113M | -64.8% | - | JPY 155M impairment loss booked as extraordinary loss following decision to sell employee dormitory |
| EPS | JPY 4.59 | -64.7% | - | Full-year EPS plan of JPY 119.34 (before reflecting the impact of share buybacks) |
Note: Net Income refers to quarterly Net Income Attributable to Owners of Parent Company. As the company discloses only full-year guidance, "vs. Company Plan" is shown as "-" and progress rates are provided in Remarks.
Guidance Achievement Rate (Recurring Profit Basis): 9.6% (past four-year average: 9.7%) Note: The prior-year figure represents prior-year 1Q Recurring Profit of JPY 509M as a percentage of full-year actual of JPY 4,018M (our estimate).
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.